Syntrix Biosystems announces the award of a grant from the National Institutes of Health (NIH) to support Phase 2 clinical trials of aminopterin in psoriasis

Auburn, WA, September 1, 2006.  Syntrix Biosystems announced today the receipt of a grant from the National Institute of Health (NIH) totaling $800,000.  The grant was awarded under the Small Business Innovative Research (SBIR) program, and will be used to fund a Phase 2 trial of aminopterin in psoriasis.  The awarded grants will expand work by the company in bringing aminopterin to market.

Dr. John Zebala, President and CEO of Syntrix Biosystems, commented that "the new support from the NIH is an important step towards developing aminopterin for the treatment of millions who suffer from psoriasis."

Syntrix Biosystems is a privately held biotechnology company founded in 1999 with research and development facilities located in Auburn, WA.  The company is developing products that meet the needs of the pharmaceutical, biotechnology, and academic research markets.  The Syntrix Biosystems website is located at www.syntrixbio.com.  For more information contact:

John A. Zebala, M.D., Ph.D.

President and CEO

jzebala@syntrixbio.com